L-741,604

L-741,604 is a **potent, selective serotonin 5-HT1D receptor agonist** that was developed primarily for its potential as an antimigraine agent. In preclinical models, L-741,604 exhibited strong **inhibitory effects on trigeminally- and spinally-mediated reflexes**, which were reversed by selective antagonists, supporting its specificity for the serotonin 5-HT1B/1D receptors. Its mechanism of action is linked to the modulation of nociceptive (pain) pathways, suggesting a role in treating migraine and possibly other pain or reflex conditions. Development was by Merck & Co., but no evidence of clinical development beyond preclinical testing has been found[1][3].

Other names

L-741,604